Drug Profile
CXCR2 antagonist - Ablynx/Novartis
Alternative Names: anti-CXCR2 Nanobody - Ablynx/NovartisLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Ablynx
- Developer Ablynx; Novartis
- Class Anti-inflammatories; Proteins
- Mechanism of Action Interleukin 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Inflammation in Belgium (Parenteral)
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 20 Feb 2017 Phase-I clinical trials in Inflammation in Belgium (Parenteral) before February 2017 (Ablynx pipeline, February 2017)